Unleashing the full power of next gen bioanalytics on cell therapy development

Cell & Gene Therapy Insights 2021; 7(4), 521–530


Published: 13 May 2021
Eric Alonzo, PhD

Dr Eric Alonzo, serves as the CMC Lead for the bbT369, a pre-clinical program for the treatment of B-NHL and Analytical Strategy Lead for the Oncology Divsion at bluebird bio. Previously, Dr Alonzo led the Oncology Characterization Team where he focused on the development of analytical and characterization assays for CAR T/TCR cell programs. Prior to bluebird bio, Dr Alonzo lead efforts developing T cell-based therapies at Agenus, and previous to his work at Agenus, he was a postdoctoral fellow at Harvard Medical School studying transcriptional and epigenetic dysregulation that leads to the development of T cell acute lymphoblastic leukemia. Dr Alonzo received his PhD from the Cancer Biology Program at the Memorial Sloan-Kettering Cancer Center.